Broadcast Date: April 15, 2021
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

Vaccine design and development have always been an integral part of the biopharmaceutical industry. Yet events that have transpired over the last year dramatically underscore the need to advance novel methodologies to generate safe and efficacious therapies quickly. Investigators face numerous challenges during the vaccine discovery process, with rapidly mutating pathogens being chief among them, as they render vaccine responses obsolete.

In this GEN webinar, our distinguished speaker Dr. Jacob Glanville, CEO and president of Centivax, will present data on computational immunology interrogation of the adaptive immune response to better understand why immune responses rarely target conserved epitopes. Moreover, we will learn how the Centivax Conservation-Concentration-Coupling (C3) technology has been designed to overcome this in-vivo limitation. By partnering with Sino Biological’s variant manufacturing expertise in polymorphic viral proteins, Dr. Glanville will show data of potent in-vivo elicitation of broad-spectrum immune responses to influenza, including neutralizing titers against future pandemic strains. R&D Manager of Sino Biological, Dr. Yuning Chen, will also share with us the viral antigen bank they’ve developed. Finally, our presenters will discuss ongoing efforts in new pathogen arenas, including the novel coronavirus and HIV.

A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.

Jacob Glanville, PhD
Jacob Glanville, PhD
CEO & President
Centivax
Yuning Chen, PhD
Yuning Chen, PhD
R&D Manager
Sino Biological